We are live on ! Find out more
ProShare Advisors

ProShare Advisors Portfolio holdings

AUM $67.5B
1-Year Est. Return 28.09%
This Fund
S&P 500
This Quarter Est. Return
+14.47%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$16.7B
AUM Growth
+$2.43B
Cap. Flow
+$474M
Cap. Flow %
2.84%
Top 10 Hldgs %
21.56%
Holding
1,687
New
116
Increased
1,133
Reduced
405
Closed
29

Top Buys

Rank Stock Value
1
RTX icon
RTX Corp
RTX
+$74.8M
2
PBCT
People's United Financial Inc
PBCT
+$73.6M
3
CB icon
Chubb
CB
+$72.7M
4
CAT icon
Caterpillar
CAT
+$71.4M
5
TGT icon
Target
TGT
+$12.7M

Sector Composition

Rank Sector Weight
1 Technology 19.51%
2 Financials 12.5%
3 Healthcare 12.23%
4 Industrials 11.06%
5 Consumer Discretionary 10.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DOVA
1576
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$97K ﹤0.01%
10,860
+72
+0.7% +$584
VSTM icon
1577
Verastem
VSTM
$532M
$96K ﹤0.01%
2,712
+24
+0.9% +$948
ACCO icon
1578
Acco Brands
ACCO
$369M
$95K ﹤0.01%
11,064
+159
+1% +$1.39K
AMKR icon
1579
Amkor Technology
AMKR
$16.1B
$95K ﹤0.01%
11,127
+343
+3% +$2.84K
NVAX icon
1580
Novavax
NVAX
$1.23B
$94K ﹤0.01%
8,575
+78
+0.9% +$2.46K
SYRE icon
1581
Spyre Therapeutics
SYRE
$8.87B
$92K ﹤0.01%
+456
New +$95.1K
SBBP
1582
DELISTED
Strongbridge Biopharma plc.
SBBP
$92K ﹤0.01%
18,398
+2,403
+15% +$11.8K
TLPH icon
1583
Talphera
TLPH
$70.1M
$90K ﹤0.01%
1,300
+251
+24% +$14.6K
CDE icon
1584
Coeur Mining
CDE
$15.6B
$84K ﹤0.01%
20,592
+1,025
+5% +$4.95K
ADMS
1585
DELISTED
Adamas Pharmaceuticals
ADMS
$83K ﹤0.01%
11,704
+93
+0.8% +$836
HMHC
1586
DELISTED
Houghton Mifflin Harcourt Company
HMHC
$82K ﹤0.01%
11,251
+347
+3% +$3.12K
ABUS icon
1587
Arbutus Biopharma
ABUS
$865M
$81K ﹤0.01%
22,682
+161
+0.7% +$618
GPRO icon
1588
GoPro
GPRO
$116M
$81K ﹤0.01%
12,494
+386
+3% +$2.16K
RAD
1589
DELISTED
Rite Aid Corporation
RAD
$79K ﹤0.01%
6,241
+247
+4% +$3.81K
SYBX
1590
DELISTED
Synlogic
SYBX
$78K ﹤0.01%
688
+5
+0.7% +$613
PETX
1591
DELISTED
Aratana Therapeutics, Inc.
PETX
$78K ﹤0.01%
21,557
+168
+0.8% +$728
PRTK
1592
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$77K ﹤0.01%
14,417
+205
+1% +$1.32K
CHS
1593
DELISTED
Chicos FAS, Inc.
CHS
$73K ﹤0.01%
17,143
+383
+2% +$2.12K
AUD
1594
DELISTED
Audacy, Inc.
AUD
$73K ﹤0.01%
13,924
+433
+3% +$2.87K
ACET icon
1595
Adicet Bio
ACET
$72.8M
$71K ﹤0.01%
93
+1
+1% +$909
OCUL icon
1596
Ocular Therapeutix
OCUL
$1.86B
$71K ﹤0.01%
17,889
+444
+3% +$1.78K
INFN
1597
DELISTED
Infinera Corporation Common Stock
INFN
$71K ﹤0.01%
16,402
+509
+3% +$2.35K
WTI icon
1598
W&T Offshore
WTI
$545M
$70K ﹤0.01%
+10,085
New +$54.8K
SIOX
1599
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$70K ﹤0.01%
6,605
+1,424
+27% +$14.2K
FOMX
1600
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$69K ﹤0.01%
18,468
+69
+0.4% +$259

Similar funds

ProShare Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, ProShare Advisors held 1,687 positions worth $16.7B, up 17% from $14.3B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

ProShare Advisors's Q1 2019 filing shows 116 new, 1,133 increased, 405 reduced and 29 closed positions. Its largest new stake was Fox Class A: 268,496 shares worth $9.86M. The largest sale was Twenty-First Century Fox, Inc. Class A, an estimated $39M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.

  • ProShare Advisors's largest Q1 2019 buy was Fox Class A: 268,496 shares worth $9.86M.
  • ProShare Advisors added most to RTX Corp in Q1 2019, an estimated $74.8M increase.
  • ProShare Advisors's biggest Q1 2019 reduction was Apple, cutting an estimated $9.37M.
  • ProShare Advisors fully exited Twenty-First Century Fox, Inc. Class A in Q1 2019, selling an estimated $39M.
  • ProShare Advisors's ten largest holdings make up 22% of its $16.7B portfolio in Q1 2019.
  • ProShare Advisors opened 116 new positions and closed 29 in Q1 2019.
  • ProShare Advisors's portfolio value rose 17% quarter-over-quarter to $16.7B.

Based on ProShare Advisors's 13F filing for Q1 2019, filed 15 May 2019.